Vimarsana
Biggest News Aggregation in the World

Page 21 - Framework Programme News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Framework Programme. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Framework Programme Today - Breaking & Trending Today

Europe Daily News, 14 September 2022 | Perspectives & Events - Vimarsana News

Europe Daily News, 14 September 2022 | Perspectives & Events

Europe Daily News, the latest policy and legal developments in the European Union

Kindergarten Thienkamp in Wiefelstede: Spendenaktion für Borbeckerin Antje Strahler - Vimarsana News

Kindergarten Thienkamp in Wiefelstede: Spendenaktion für Borbeckerin Antje Strahler

Ende Juni erlitt die Borbeckerin Antje Strahler einen Schlaganfall. Der Wiefelstede Kindergarten Thienkamp will der Familie helfen und organisiert eine Spendenaktion.

Centre-right manifesto to stress Italy place in NATO,EU (12) - English Service - Vimarsana News

Centre-right manifesto to stress Italy place in NATO,EU (12) - English Service

An initial draft of the right/centre-right coalition's manifesto for the September 25 general election, which ANSA has seen, stresses that Italy would maintain its position at the centre of the European Union and NATO with a government led by it. © ANSA

Source: ansa.it
EU's Project Phoenix is Helping Nanopharmaceuticals Take Flight - Vimarsana News

EU's Project Phoenix is Helping Nanopharmaceuticals Take Flight

A novel nanomedicine initiative, Project Phoenix, has been funded by the EU’s Horizon2020 Framework Programme, which comprises 11 project partners from academia and industry within Europe.

Dompé Farmaceutici S.p.A: Two Clinical Studies to Treat Mild-to-Moderate COVID-19 at Home Reveal Value of Exscalate, Dompé's AI Platform for Drug Design - Vimarsana News

Dompé Farmaceutici S.p.A: Two Clinical Studies to Treat Mild-to-Moderate COVID-19 at Home Reveal Value of Exscalate, Dompé's AI Platform for Drug Design

Two papers, published in The Lancet and Nature, indicate that treatment with oral raloxifene, a selective estrogen receptor modulator (SERM) with a proven safety profile, may be efficacious